Navigation Links
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
Date:10/1/2009

OSAKA, Japan, Oct. 1 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets," said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the world and accounts for approximately 25 percent of the pharmaceutical sales throughout Latin America. The population in Mexico is increasing, and access to healthcare continues to grow, with the market increasing faster than in the United States and Europe, making it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe - Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceutical market size which accounts for five percent of the European pharmaceutical market. Following the buy-back of Actos® (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries. The creation of these commercial subsidiaries will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global pharmaceutical markets, ranked sixth in Europe and 13th worldwide with the fastest forecasted growth rate in Europe over the next five years. Takeda also recently re-acquired the rights to Actos in this market, providing the business with a strong product with which to enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion efforts for core products including Actos and reinforces Takeda's global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda's presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit http://www.takeda.com/.

About Takeda Pharmaceuticals Mexico, S.A. de C.V.

    Name:           Takeda Pharmaceuticals Mexico, S.A. de C.V.
    Location:      Mexico city, Mexico
    Established:  October 2009

About Takeda Pharmaceuticals Nordics AB

    Name:           Takeda Pharmaceuticals Nordics AB
    Location:      Sweden
    Established:  October 2009

About Takeda Pharmaceuticals Benelux SPRL

    Name:           Takeda Pharmaceuticals Benelux SPRL
    Location:      Belgium
    Established:  October 2009

About Takeda Pharmaceuticals Trade, LLP

    Name:           Takeda Pharmaceuticals Trade, LLP
    Location:      Istanbul, Turkey
    Established:  October 2009

SOURCE Takeda Pharmaceutical Company Limited


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
2. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
4. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
5. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... In a new paper published in the ... Rod J. Rohrich, and colleagues, examine and underscore the importance of upper lateral ... when addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers ...
(Date:2/11/2016)... Mount Laurel, NJ (PRWEB) , ... February 11, ... ... Commission) announces the call for nominations seeking candidates for the Board of Commissioners. ... individuals with passion, skills and experience with diversity of clinical practice settings and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing curves. It’s thrown ... who gather once a year to play softball to raise money through Sun ... more than 50 players who competed in this year’s softball tournament share a history ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment to ... support of a local boy named Barrett, who has been fighting ALL leukemia for ... rally support for, all local families dealing with childhood cancer. Information on how to ...
Breaking Medicine News(10 mins):